(Q40363507)

19 September 2017

Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration (English)

1 reference

19 September 2017

0 references

Jeffrey M Craft

1

1 reference

PubMed ID

16369931

19 September 2017

D Martin Watterson

series ordinal

2

1 reference

PubMed ID

16369931

19 September 2017

Linda J Van Eldik

series ordinal

3

1 reference

19 September 2017

1 April 2006

1 reference

19 September 2017

1 reference

19 September 2017

53

1 reference

19 September 2017

5

1 reference

19 September 2017

484-490

1 reference

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

19 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Enhanced susceptibility of S-100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human beta-amyloid

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Drug-induced hepatotoxicity.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Neuroscience. The dark side of glia.

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: a foundation for future medicinal chemistry efforts focused on targeting Alzheimer's

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Discovery of new chemical classes of synthetic ligands that suppress neuroinflammatory responses

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Spatial learning and memory in aging C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.20306

7 January 2021

Identifiers

DOI

10.1002/GLIA.20306

1 reference

19 September 2017

1 reference

PubMed ID

16369931